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1. INTRODUCTION {#hbm25083-sec-0001}
===============

AD is one of the leading causes of death and disability in the elderly for which no disease‐modifying treatment yet exists. Thus far, interventional trials to slow the progression of AD have failed (Cummings, [2018](#hbm25083-bib-0006){ref-type="ref"}). The mild and heterogeneous presentation at the early stage of AD reduces the accuracy of the available diagnostic criteria, which prevents timely initiation of potentially effective therapies. Advancement in the development of noninvasive biomarkers is expected to aid in early diagnosis and prognostic stratification of AD.

A number of MRI measures have been suggested to have potential for AD diagnosis and longitudinal monitoring. These include loss of hippocampal volume (Schuff et al., [2009](#hbm25083-bib-0035){ref-type="ref"}), reduced thickness of the entorhinal cortex (Velayudhan et al., [2013](#hbm25083-bib-0042){ref-type="ref"}) and increased volume of the lateral ventricles (Nestor et al., [2008](#hbm25083-bib-0028){ref-type="ref"}). Most of these imaging features were chosen based on a priori assumptions of the boundaries of anatomical structures involved in the disease process. However, the sensitivity of a priori‐driven approaches that single out a particular brain region such as the hippocampus is limited by heterogeneity of AD, which translates to different patterns of brain degeneration in different patients (Marquand, Rezek, Buitelaar, & Beckmann, [2016](#hbm25083-bib-0026){ref-type="ref"}). The region‐of‐interest studies also disregard the spatial continuity across brain areas (Haak, Marquand, & Beckmann, [2018](#hbm25083-bib-0015){ref-type="ref"}) and the covariance within and across brain networks (Xu, Groth, Pearlson, Schretlen, & Calhoun, [2009](#hbm25083-bib-0044){ref-type="ref"}). Exploratory methods such as independent component‐analysis (ICA) can circumvent this problem, by providing a data‐driven picture of the affected brain networks, and thereby track the impact of the disease in a hypothesis‐free manner. Instead of imposing categorical or binary boundaries onto the data, feature extraction methods like ICA transform the data into features based on the inherent---in this case spatial---structure of the data. Staying closer to the inherent biological data structure allows more relevant variance to be maintained, which benefits the sensitivity of subsequent analyses. ICA also reduces the number of statistical tests without resorting to a priori regions of interest, which in most scenarios would substantially boost statistical power in the face of multiple testing. This is particularly true for genome‐wide association studies of millions of variants. At the same time ICA also aids interpretability of high‐dimensional data, by describing the data in terms of a smaller number of relevant variables (i.e., components or features).

AD is highly heritable at h2 = 0.58--0.79 (Gatz et al., [2006](#hbm25083-bib-0013){ref-type="ref"}). APOE4, which is the strongest genetic risk factor for sporadic late‐onset AD, explains only a quarter of this genetic variance. The novel risk variants discovered by genome‐wide association studies (GWAS) explain an even smaller proportion of AD heritability (Jansen et al., [2019](#hbm25083-bib-0019){ref-type="ref"}). These studies commonly rely on diagnostic instruments for the dichotomous definition of the disease versus the healthy state. However, diagnostic instruments are originally aimed at guiding decisions in the clinic and capture mostly the terminal events of the disease pathways. Pathological brain changes are often reflected in neuroimaging data prior to the onset of clinical signs (Piers, [2018](#hbm25083-bib-0031){ref-type="ref"}; Tabatabaei‐Jafari, Shaw, Walsh, Cherbuin, & Initiative, [2019](#hbm25083-bib-0040){ref-type="ref"}). Quantitative neuroimaging may therefore be more sensitive to the genetic determinants of AD at early stages, when the clinical presentation does not yet fulfill the diagnostic criteria.

Here, we used ICA of pre‐processed structural brain MRI data in a longitudinal cohort of elderly subjects to arrive at a data‐driven pattern of brain degeneration in AD and mild cognitive impairment (MCI). We then performed a genome‐wide search for genetic variants associated with structural integrity of this disease‐related brain feature. Finally, we validated the genome‐wide association with structure of the medial temporal cortex in an independent sample. The effect of the variant on parental history of AD, as a proxy to dementia predisposition, was also assessed.

2. METHODS {#hbm25083-sec-0002}
==========

2.1. ADNI participants {#hbm25083-sec-0003}
----------------------

Imaging, whole‐genome sequencing and clinical data used in the discovery phase of this study were obtained from the ADNI database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). ADNI is a multi‐center initiative led by principal investigator Michael W. Weiner, MD, VA Medical Center and University of California, San Francisco, and enrolls subjects with normal cognition, MCI and AD. Our investigation included 1,100 ADNI individuals (age: 74.0 ± 7.1 year, Table [1](#hbm25083-tbl-0001){ref-type="table"}) with baseline T1‐weighted brain MRI scans. Longitudinal MRI scans were available in a subsample of 1,039 subjects who underwent follow‐up imaging at 1.07 ± 0.08 year (*n* = 1,009 subjects) and/or 2.07 ± 0.11 year intervals (*n* = 883 subjects).

###### 

Study subjects

                    CN    MCI   AD    Total (female)
  ----------------- ----- ----- ----- ----------------
  Cross‐sectional   383   456   361   1,100 (491)
  Longitudinal      269   422   348   1,039 (457)
  GWAS              226   402   180   808 (363)

Cognitively healthy individuals were defined by Mini Mental State Examination (MMSE) scores between 24 and 30, CDR of zero, and by the absence of depression, dementia, and any sign of cognitive impairment. MCI subjects were defined by MMSE scores between 24 and 30, memory complaints with objective memory loss as measured by education‐adjusted scores on Wechsler Memory Scale‐Revised (WMS‐R) logical memory II, a CDR of 0.5, absence of significant impairment in other cognitive domains and absence of dementia. AD patients had MMSE score between 20 and 26, CDR of 0.5 or 1.0 and fulfilled NINCDS/ADRDA criteria for probable AD.

2.2. UK Biobank {#hbm25083-sec-0004}
---------------

The UK Biobank dataset was used for validation of our ADNI analysis results (Sudlow et al., [2015](#hbm25083-bib-0039){ref-type="ref"}) including subjects with the age at baseline range of 40--69 years. Association of brain imaging‐derived phenotypes (IDPs) with genome‐wide variants has been previously investigated in 8,428 subjects scanned by MRI and data is publically available across 11,734,353 SNPs (Elliott et al., [2018](#hbm25083-bib-0010){ref-type="ref"}). For our work, we extracted summary statistics of cortical thickness (<http://big.stats.ox.ac.uk>) for the top‐hit variant of the ADNI association study in UK Biobank and visualized it on a standard FreeSurfer parcellation atlas. In addition, genome‐wide statistics of the paternal (*n* = 292,053 subjects) and maternal (*n* = 308,780 subjects) history of AD were retrieved from an independent GWAS of UK Biobank cohort (<https://github.com/nealelab/uk_biobank_gwas>). We performed a fixed‐effect meta‐analysis on the maternal and paternal SNP effect sizes and obtained genome‐wide variants associated with history of AD in parents, similar to the recent AD‐by‐proxy approach (Jansen et al., [2019](#hbm25083-bib-0019){ref-type="ref"}; Marioni et al., [2018](#hbm25083-bib-0025){ref-type="ref"}).

2.3. Brain atrophy estimation and diagnosis discrimination using independent component analysis {#hbm25083-sec-0005}
-----------------------------------------------------------------------------------------------

We registered all MRI volumes to construct a minimum‐deformation study brain template in four linear and four nonlinear iterations using SyN (Avants et al., [2010](#hbm25083-bib-0002){ref-type="ref"}). Cross‐sectional TBM was used to identify voxel‐wise brain volume differences at baseline across 1,100 study subjects. Longitudinal tensor‐based morphometry (TBM) was also performed to calculate voxel‐wise progression of brain atrophy and its annual rate in all individuals with follow‐up MRI scans (*n* = 1,039), using extensively validated methods (Figure [1](#hbm25083-fig-0001){ref-type="fig"}) (Yushkevich et al., [2010](#hbm25083-bib-0045){ref-type="ref"}). Both of the cross‐sectional and longitudinal pipelines yielded SyN Jacobian determinant maps, which respectively reflect voxel‐wise differences in regional brain volume of each subject compared to the common template at baseline, or the annual rate of brain volume loss in each subject in course of the disease. The average maps of the longitudinal rates of change for each diagnostic group are shown in Figure [S1](#hbm25083-supitem-0001){ref-type="supplementary-material"}. These Jacobian maps were then decomposed into independent sources by ICA.

![Outline of the Study methods. T1‐weighted MRIs were used to identify structural brain changes in cross‐sectional and longitudinal studies. ICA decomposed 1,348 spatial sources of brain morphometry, among which the medial temporal circuit (MTC) was replicated as the top imaging predictor of AD and MCI and subsequently brought to GWAS](HBM-41-3737-g001){#hbm25083-fig-0001}

ICA is an exploratory method for linearly decomposing neuroimaging data into 3D spatial maps and subject‐wise loadings, and has shown to effectively separate neural processes of different origins in functional (Beckmann & Smith, [2004](#hbm25083-bib-0003){ref-type="ref"}) and structural neuroimaging (Groves, Beckmann, Smith, & Woolrich, [2011](#hbm25083-bib-0014){ref-type="ref"}). To decompose maps of structural brain variation at various spatial details, ICA was performed at multiple dimensions (8, 12, 16, 20, 24, 28, 32, 40, 48, 56, 64, 72, 80, 88 and 96), yielding a total of 1,348 spatial maps of baseline brain volume (*n* = 684 maps) and of longitudinal atrophy (*n* = 664 maps). The extracted components represent brain regions with structural covariance across the study population, that is, areas that tend to lose volume with statistically correlated trajectories possibly due to a common underlying pathology. In ICA, subject‐wise loading values linearly reflect each subject\'s level of brain volume (in cross‐sectional morphometry) or atrophy rate (in longitudinal morphometry) within each 3D spatial map (for further details, see [Appendix](#hbm25083-supitem-0003){ref-type="supplementary-material"} S1). To find out which of the brain components were related to AD, they were used as predictor variables in L1‐regularized (LASSO) logistic regression models (Tibshirani, [1996](#hbm25083-bib-0041){ref-type="ref"}) to discriminate AD patients or MCI subjects from the cognitively normal group ([Figure S2](#hbm25083-supitem-0001){ref-type="supplementary-material"}). Leave‐one‐out cross validation was used to optimize the L1 regularization parameter (λ) and achieve maximum classification accuracy in the dichotomous case/control logistic discriminations. Regression beta estimates (log odds ratios) were then compared across all brain components to identify the single component with the highest association with AD in cross‐sectional and longitudinal data, controlling for subjects\' age and sex.

### 2.3.1. Correlation of MRI feature with clinical ADAS score {#hbm25083-sec-0006}

Correlation of the top AD‐associated brain component was investigated with cognitive performance at baseline as measured by the ADAS‐cog‐13 scale (Skinner et al., [2012](#hbm25083-bib-0037){ref-type="ref"}). The analysis was performed separately for baseline volume measure and longitudinal atrophy rate of the top component in AD (*n* = 361 cross‐sectional, 348 longitudinal) and MCI (*n* = 456 cross‐sectional, 422 longitudinal) subjects, controlling for age and sex covariates in a general linear model.

2.4. Genome‐wide association study {#hbm25083-sec-0007}
----------------------------------

The AD‐associated imaging feature was brought to genome‐wide association analysis to identify genetic drives of structural brain deficits in disease‐vulnerable regions. Whole‐genome sequencing data was collected at an average depth of 30--40× in 808 participants, from which a total of 38,566,438 single‐nucleotide polymorphisms (SNPs) and 5,969,342 short insertion‐deletions (indels) were called using Genome Analysis Toolkit (GATK) (DePristo et al., [2011](#hbm25083-bib-0008){ref-type="ref"}; Saykin et al., [2015](#hbm25083-bib-0034){ref-type="ref"}). Variants were filtered by considering minor phred quality score of 30, minor allele frequency of 0.01, minimum variant genotyping rate of 0.9 and Hardy--Weinberg Equilibrium state of *p* \> 1 × 10^−6^, resulting in inclusion of 10,957,927 QC‐passed variants for whole‐genome association. We chose the WGS data over the imputed DNA array genotypes for higher coverage and variant calling density of the former platform, as chip arrays do not capture the total extent of genomic variation in each individual and some causal variants may be missed due to poor imputation. We searched for genetic variants correlated with baseline volume of the top AD‐associated brain component in all study subjects (Table [1](#hbm25083-tbl-0001){ref-type="table"}). The GWAS regression model included age, sex, the diagnosis groups (AD, MCI, cognitively normal), three principal axes of population structure, MRI pulse sequence (MP‐RAGE vs. SPGR), and the APOE4 allele dosage as covariates. Our analysis showed that field strength, voxel‐size, MRI vendor and the pulse sequence type (MP‐RAGE vs. IR‐SPGR) do not significantly affect the ICA phenotype, but we regress out the pulse sequence type from the data as it explained more variance than the rest.

3. RESULTS {#hbm25083-sec-0008}
==========

3.1. Strong structural covariance in Alzheimer\'s disease‐affected brain regions: Independent component analysis {#hbm25083-sec-0009}
----------------------------------------------------------------------------------------------------------------

ICA identified latent sources in brain morphometry maps that mapped to anatomically and functionally coherent regions ([Figure S3](#hbm25083-supitem-0001){ref-type="supplementary-material"}). Following the two‐class LASSO logistic regressions, AD patients could be classified by reduced volume of 26 brain components (out of 684) in cross‐sectional MRI from the healthy group, or 30 components (out of 664) in longitudinal MRI, with respective classification accuracies of 86% and 87% as assessed by leave‐one‐out cross validation (Table [1](#hbm25083-tbl-0001){ref-type="table"}). These component counts reflect the point of saturation in the LASSO regression model, that is, classification accuracy will no longer significantly increase by inclusion of more components ([Figure S2](#hbm25083-supitem-0001){ref-type="supplementary-material"}). The cross‐sectional components predicting AD diagnosis clustered to: precuneus, occipital lobes and pulvinar (Figure [2a](#hbm25083-fig-0002){ref-type="fig"}); a robust cluster including hippocampi, amygdalae, parahippocampal gyri, fornix, mammillary bodies, and uncinate fasciculi (Figure [2b](#hbm25083-fig-0002){ref-type="fig"}); as well as lateral temporal lobes and the cerebellum (Figure [2c](#hbm25083-fig-0002){ref-type="fig"}). The AD‐predicting components in longitudinal TBM clustered to: precuneus, cuneus and occipito‐parietal lobes (Figure [2d](#hbm25083-fig-0002){ref-type="fig"}); thalamus, temporal lobes and its association areas (Figure [2e](#hbm25083-fig-0002){ref-type="fig"}); medial temporal lobes, uncinate fasciculus and the orbitofrontal cortex (Figure [2f](#hbm25083-fig-0002){ref-type="fig"}); as well as insula, basal ganglia and cerebellum (Figure [2g](#hbm25083-fig-0002){ref-type="fig"}).

![Brain components related to Alzheimer's disease. Left: Cross‐correlation matrices of brain components that discriminated AD patients from cognitively normal subjects were constructed. Hierarchical clustering was then applied to these matrices to group similar components together. Right: cluster‐wise sum of the z‐score maps of the components are shown (red‐yellow: atrophy, blue: expansion; thresholded via mixture modeling. The strongest AD discriminator in both analyses was a component referred to as the medial temporal circuit (MTC) in this paper, which is plotted as the yellow diagonal element in both matrices. This component (see volume rendered [video S1](#hbm25083-supitem-0002){ref-type="supplementary-material"}) was the focus of brain atrophy in a cluster of components mapping to temporal lobes (b and f). Brain morphometry results also showed other clusters of structural brain deficits in AD that map to the posterior brain/occipitoparietal regions (a, d) and lateral temporal, insular and subcortical areas (c, e, g)](HBM-41-3737-g002){#hbm25083-fig-0002}

3.2. Early degeneration of the limbic system in Alzheimer\'s disease {#hbm25083-sec-0010}
--------------------------------------------------------------------

The most prominent predictor of AD was a component that obtained the top odds‐ratio rank in both the cross‐sectional and the longitudinal analyses in discriminating AD from the cognitively‐normal subjects. This component, referred to as the *Medial Temporal Circuit* (MTC) in this paper, was also a predictor of subjects with MCI, obtaining the top odds‐ratio rank in discriminating MCI subjects from the cognitively normal group in cross‐sectional brain morphometry (Figure [3](#hbm25083-fig-0003){ref-type="fig"}). The MTC demonstrated a bilateral network‐like topology (see [video S1](#hbm25083-supitem-0002){ref-type="supplementary-material"}). The focus of brain atrophy in the MTC localized to the bilateral amygdalae, and further extended to the hippocampi, entorhinal cortex, insula, mammillary bodies, and the fornix.

![Contribution of brain components in predicting subjects' cognitive status. Each bar represents a brain component that was able to distinguish MCI subjects (left plots) and/or AD patients (right plots) from the cognitively normal subjects in L1 regression models. Bar lengths encode log odds ratios reflecting the importance of each component in diagnosis classification. Both models in cross‐sectional (top) and longitudinal neuroimaging (bottom) consistently identified the MTC component as the strongest predictor of AD and MCI (red bars). The top figure shows multiple bars reflecting the MTC, corresponding to different dimensionalities (See [Appendix](#hbm25083-supitem-0003){ref-type="supplementary-material"} S1). Each voxel's contribution to the MTC is depicted in the figure on the right, for both the cross‐sectional and the longitudinal decompositions](HBM-41-3737-g003){#hbm25083-fig-0003}

Although the MTC included the hippocampus, it had a better discriminatory power for MCI subjects than hippocampus per se (Welch\'s *t* = 4.4: *p* = 1.2 × 10^−5^ vs. *t* = 3.2: *p* =  .002 for MTC and hippocampus, respectively). The MTC also showed much higher statistical power than hippocampal volume for group‐wide discrimination of the AD from the cognitively normal group, although subject to circularity (Welch\'s *t* = 16.8: *p* \< 10^−15^ vs. *t* = 4.4: *p* = 1.1 × 10^−5^ for MTC and hippocampus, respectively).

3.3. Reduction of brain volume in the medial temporal component and cognitive decline {#hbm25083-sec-0011}
-------------------------------------------------------------------------------------

Cognitive performance of participants, as measured by ADAS‐cog, was correlated with MTC at its baseline volume in AD (*p* = 5.4 × 10^−8^) and MCI (*p* = 9.6 × 10^−7^), adjusted for age and sex. Similarly, the atrophy rate in MTC showed significant associations with ADAS‐cog in AD (*p* = .04) and MCI subjects (*p* = .002) adjusted for age and sex. Older age (*p* = 2.6 × 10^−5^) and female sex (*p* = 7.5 × 10^−5^) were associated with faster atrophy in this imaging feature. Compared to the cognitively normal group, the annual atrophy rate in the MTC was increased by 2.1‐fold in MCI and 5.1‐fold in AD patients.

3.4. Genetic modifiers of brain volume in the medial temporal component {#hbm25083-sec-0012}
-----------------------------------------------------------------------

GWAS revealed a single missense SNP in the SHARPIN gene, rs34173062, which was genome‐wide significant at *p* = 2.1 × 10^−10^ (normalized beta = −.2; Figures [4](#hbm25083-fig-0004){ref-type="fig"} and [S4](#hbm25083-supitem-0001){ref-type="supplementary-material"}). Genomic inflation (λ) was calculated at 1.028. Two other trend‐level variants (*p* \< 10^−6^) were located in the introns of EPHA7 and FRMD4A (Table [2](#hbm25083-tbl-0002){ref-type="table"}). The APOE locus was associated with the MRI feature at *p* = .0047. We tested 28 other AD risk loci of the latest AD GWAS (Jansen et al., 2019), and none of the risk variants passed multiple comparisons corrections. There were two weak signals for HLA‐DRB1 and PICALM loci at the same direction (*p* = .013 and .026 respectively), but general sign‐concordance was a trend at *p* =  .068. Performing the GWAS without conditioning on APOEε4 did not substantially affect the top variants statistics, and SHARPIN remained the single genome‐wide significant locus at *p* = 6.3 × 10^−10^. MRI pulse sequence (MP‐RAGE vs. IR‐SPGR) did not affect the ICA‐extracted measure (*p* = .8). We sought validation of the SHARPIN variant in the UK Biobank cohort in which rs34173062 was directly genotyped by the Axiom genotyping array (Elliott et al., [2018](#hbm25083-bib-0010){ref-type="ref"}), showing a minor allele frequency of 0.07. In this cohort (*n* = 8,428 subjects), rs34173062 was associated with reduced thickness of the entorhinal cortex in left (*p* = .002) and right (*p* = 8.6 × 10^−4^) hemispheres, in the same direction as in the ADNI discovery sample (effect allele: A‐allele; effect size on unit‐variance normalized phenotype = −0.1, Figure [5](#hbm25083-fig-0005){ref-type="fig"}). As the age of the UK Biobank subjects (49--69 years) is relatively young for clinical presentation of late‐onset AD, we further searched for parental history of AD as a proxy to its heritable component. The risk allele (rs34173062‐A) was significantly associated with increased maternal (*p* = .0012) and paternal (*p* = 5.1 × 10^−4^) history of AD, which translates to a fixed‐effect meta‐analysis p‐value of 2.3 × 10^−6^ in both parents with a consistent effect direction (Figure [4](#hbm25083-fig-0004){ref-type="fig"}, regional association plot).

![Manhattan and regional association plots of the SHARPIN locus. Left: association of the SHAPRIN locus with medial temporal lobe volume (ADNI) and parental history of AD (UK Biobank). Right: Manhattan plot showing genome‐wide association of SHARPIN locus with medial temporal lobe volume in ADNI](HBM-41-3737-g004){#hbm25083-fig-0004}

###### 

GWAS top SNPs

  SNP                                                   Chr   Position (hg19)   A1   A2 (effect)   Frequency   *β*    Gene mapping         *p*‐value
  ----------------------------------------------------- ----- ----------------- ---- ------------- ----------- ------ -------------------- ---------------
  rs56112946[^a^](#hbm25083-note-0001){ref-type="fn"}   3     197,077,194       C    T             0.03        −.15   ‐                    3.1 × 10^−7^
  rs3778470                                             6     94,075,684        G    A             0.12        −.15   EPHA7 (intronic)     1.5 × 10^−7^
  rs149101079                                           8     69,347,181        G    A             0.04        −.15   C8orf34              3.1 × 10^−7^
  rs34173062                                            8     145,158,607       G    A             0.10        −.19   SHARPIN (missense)   2.1 × 10^−10^
  rs28439901                                            10    14,494,941        G    A             0.08        −.15   FRMD4A (intronic)    3.2 × 10^−7^

In linkage disequilibrium with rs55672024 (*r* ^2^ = .96).

![Association of rs34173062 with cortical thickness. Thickness of bilateral entorhinal cortices (red) was significantly associated with rs34173062 in the UK Biobank cohort (n=8,428 subjects)](HBM-41-3737-g005){#hbm25083-fig-0005}

4. DISCUSSION {#hbm25083-sec-0013}
=============

Using fully data‐driven methods, we identified an anatomical feature of brain atrophy in AD, centered on the medial temporal lobes and its input/output circuits to fornix and the parahippocampal gyrus. Considering the role of this network and the associated pathways in memory mechanisms, observation of voxel‐wise covariance in its subcomponents may reflect network‐level vulnerability to a common underlying pathology in AD. This finding may be due to cellular and proteomic compositions driving brain degeneration and resulting in a symmetrical pattern of brain atrophy in the ICA probability maps. Specifically, our limbic component suggests that amygdalae are the most vulnerable structures of this network in AD, followed by bilateral hippocampi in a head‐to‐tail direction, and subsequently fimbriae and fornical tracts. This observation is consistent with a previous report showing that a healthy APOE4 carrier status is associated with abnormal brain connectivity in amygdalae and hippocampal heads, suggesting early involvement of these subregions of the medial temporal lobes in the disease trajectory (Filippini et al., [2009](#hbm25083-bib-0012){ref-type="ref"}).

Our results indicate that the parental AD‐by‐proxy phenotype is associated with a genetic modifier of a structurally disrupted limbic system as revealed by ICA and MRI. Similar to AD, the limbic component was the strongest imaging predictor of MCI, but the lower discriminatory power in MCI discrimination indicates that individuals with MCI are more similar to the healthy population in terms of this brain phenotype, and that they may represent a more heterogeneous population than the clinically probable AD group. Nevertheless, these observations support the notion that the underlying mechanisms of mild cognitive impairment partially overlap with AD. Clinical studies such as drug trials may benefit from stratifying MCI cohorts based on data‐driven imaging features of limbic integrity at baseline.

In our genetic association analysis, we identified a common variant in SHARPIN in association with the MRI feature of the limbic system. This variant substitutes an amino acid in the N‐terminal domain of the SHARPIN protein, a site responsible for its dimerization with potential roles in scaffolding as it adopts a pleckstrin homology superfold (Stieglitz, Haire, Dikic, & Rittinger, [2012](#hbm25083-bib-0038){ref-type="ref"}). Association of this variant with the history of AD in both parents, in the UK Biobank as an independent cohort comprising younger population, confirms contribution of SHARPIN to dementia heritability and early subclinical pathology. Two recent articles have implicated SHARPIN in AD, with an ultra‐rare variant in this gene at minor allele frequency of \~0.0002 discovered to increase the risk of AD to almost six‐fold in a Japanese cohort (Asanomi et al., [2019](#hbm25083-bib-0001){ref-type="ref"}; Lancour et al., [2018](#hbm25083-bib-0022){ref-type="ref"}). While this variant is not polymorphic in the western population, our study shows that another nonsynonymous variant in SHARPIN predisposes to AD and brain degeneration in the western population. The variant we observed is ultra‐rare to nonpolymorphic in the eastern Asian cohorts (\<0.01), but has a minor allele frequency of 0.04--0.13 in northern American, European and Iranian populations (Fattahi et al., [2019](#hbm25083-bib-0011){ref-type="ref"}). As a component of the postsynaptic SHANK scaffold, SHARPIN links the glutamate neurotransmitter receptors with the internal actin cytoskeleton (Lim et al., [2001](#hbm25083-bib-0023){ref-type="ref"}). SHARPIN also modulates recruitment of another AD risk gene product, Kindlin‐2, to the β1‐integrin adhesion receptors (Rantala et al., [2011](#hbm25083-bib-0032){ref-type="ref"}). We suspect that SHARPIN affects synaptic adhesion and its dysfunction may disrupt the postsynaptic scaffold. Implication of the cell adhesion pathway by SHARPIN spotlights alternate mechanisms of APP and γ‐secretase function in cell adhesion regulation, and specially direct interaction of APP with the β1‐integrin adhesion pathway (Bot, Schweizer, Ben Halima, & Fraering, [2011](#hbm25083-bib-0004){ref-type="ref"}; Sabo, Ikin, Buxbaum, & Greengard, [2001](#hbm25083-bib-0033){ref-type="ref"}).

FRMD4A and EPHA7 loci were also associated with limbic degeneration in the discovery cohort at a trend‐level (*p* \< 10^−6^). FRMD4A has been previously associated with AD (Lambert et al., [2013](#hbm25083-bib-0021){ref-type="ref"}) and codes for a scaffolding protein that connects the actin cytoskeleton with adherens junctions for cell adhesion regulation and membrane remodeling (Ikenouchi & Umeda, [2010](#hbm25083-bib-0018){ref-type="ref"}). Although the potential role of FRMD4A in neurobiology is unknown, this molecular function aligns with the mechanisms of postsynaptic adhesion and neurotransmitter receptor trafficking in synaptic plasticity. EPHA7 codes for a receptor engaged in dendritic guidance and adhesion‐regulated assembly of the synapse (Clifford et al., [2014](#hbm25083-bib-0005){ref-type="ref"}), further highlighting the cytoskeletal pathway acting downstream to the synaptic adhesion receptors in AD. A rare variant in this gene has been previously reported to segregate with the disease status in a family with autosomal dominant AD (Kunkle B.W., [2014](#hbm25083-bib-0020){ref-type="ref"}). Of note, both of these gene products interact with the (β1‐)integrin adhesion pathway, either through ARF and cytohesin (Oh & Santy, [2010](#hbm25083-bib-0029){ref-type="ref"}) or directly (Sharfe et al., [2008](#hbm25083-bib-0036){ref-type="ref"}).

While argument has been recently made for relevance of the focal adhesion pathway to elements of the amyloid cascade (Dourlen, Kilinc, Malmanche, Chapuis, & Lambert, [2019](#hbm25083-bib-0009){ref-type="ref"}), we suspect that cell adhesion may rather act independently of the amyloid cascade in the disease process. In the context of cell adhesion, SHARPIN and APP share intriguing molecular signaling mechanisms with the APOE receptors. Both APP and SHARPIN cross‐talk with the β1‐integrin pathway of cell adhesion (Rantala et al., [2011](#hbm25083-bib-0032){ref-type="ref"}; Sabo et al., [2001](#hbm25083-bib-0033){ref-type="ref"}) as does the APOE receptor LRP1 (Orr et al., [2003](#hbm25083-bib-0030){ref-type="ref"}). A recent elegant report has revealed clock‐like accumulation of somatic mutations in aging neurons of healthy humans, and this *genosenium* mechanism (Hoang et al., [2016](#hbm25083-bib-0017){ref-type="ref"}; Lodato et al., [2018](#hbm25083-bib-0024){ref-type="ref"}) may drive loss of critical synaptic adhesion regulators such as the extremely large LRP1B receptor of APOE, which has a highly brain specific expression profile paralleling areas of AD vulnerability (Haas et al., [2011](#hbm25083-bib-0016){ref-type="ref"}; Marschang et al., [2004](#hbm25083-bib-0027){ref-type="ref"}; Wu, Li, Yu, & Deng, [2008](#hbm25083-bib-0043){ref-type="ref"}). Further investigation into the effect of genosenium on synaptic adhesion regulators and their modulation by the RELN/β1‐integrin/LRP pathway may be warranted in light of the genetic liability of AD that remains unexplained by amyloid beta‐related mechanisms.

A major strength of our study is the use of ICA, which allowed us to derive a data‐driven, voxel‐wise neuroanatomical phenotype that is more sensitive to AD and MCI than the widely used hippocampal volume feature. For future researchers, it will be possible to map the AD‐relevant brain component of the medial temporal lobes to other, independent cohorts, using the voxel‐wise morphometry data and spatial regression to derive an AD‐sensitive MRI feature. Another strength is the validation of our genome‐wide significant association in a similar neuroanatomical region in an independent cohort. However, our study also has a number of limitations. It was not possible to use the clinical AD phenotype in the UK Biobank cohort due to the relatively young age distribution. The parental by‐proxy phenotype used here is confounded by recall bias and relative lack of specificity. Nevertheless, a previous study has shown that this proxy phenotype has a high level of genetic correlation (*r* = .8) with the genetic architecture of AD (Jansen et al., [2019](#hbm25083-bib-0019){ref-type="ref"}). As a second limitation, further tracking the longitudinal trajectory of brain atrophy and its association with symptoms of cognitive decline will be needed to validate the ICA‐based imaging feature of the limbic system as an early disease biomarker. We observed that except APOE, other risk loci of clinical AD were not associated with the structural MRI feature in our association study at a significant level. This divergence may either stem from limited statistical power, or indicate that brain atrophy and clinical cognitive decline are biologically inter‐related but not equivalent in their genetic underpinnings. MRI‐derived atrophy features probably reflect neuronal death aspect of AD pathophysiology that results in loss of tissue. However, genetic risk factors of clinical AD may as well act through other pathways such as functionally impairing neurotransmission efficiency and synaptic disorganization that may not be strongly reflected in structural MRI. In a recent preprint the same SHARPIN variant has been reported as a risk locus of AD in a case/control study (de Rojas et al., [2020](#hbm25083-bib-0007){ref-type="ref"}).

In conclusion, using a data‐driven decomposition of brain morphometry maps, we identify early limbic degeneration as a new imaging feature of AD, and report a novel genetic risk variant in SHARPIN associated with structural deficits of this vulnerable brain region. Our multivariate method of mining brain degeneration using structural MRI and ICA may benefit future studies of AD, including disease prognosis and treatment trials. Our results underscore SHARPIN, as a postsynaptic adhesion modulator, in pathways of neurodegeneration in AD. Frequent implication of the β1‐integrin pathway by several novel risk genes of AD including SHARPIN warrants further research.
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**Figure S1** **Tensor‐based morphometry.** Longitudinal Jacobian maps show the annual rate of brain atrophy in study diagnosis groups. CN: cognitively normal; MCI: mild cognitive impairment; AD: Alzheimer\'s disease

**Figure S2. Sparse logistic regression models for diagnosis prediction.** Leave‐one‐out cross‐validation plots for discriminating AD or MCI subjects from the cognitively normal group using all ICA components. **a)** The increase in the λ parameter (x‐axis: bottom) shrinks the L~1~ regression and results in inclusion of fewer predictor components in the diagnosis discrimination model (x‐axis: top). Separate logistic regressions were used to discriminate AD (**left**) or MCI subjects (**right**) from the cognitively normal group. **b)** Similar regression models were used in longitudinal neuroimaging to discriminate AD (**left**) or MCI subjects (**right**) from the cognitively normal group.

**Figure S3. Examples of independent components decomposed in cross‐sectional brain morphometry.** Components spanned various brain areas, including white‐matter voxels in brainstem, cerebellum and corpus callosum (a), cortical gyri and sulci in occipital and frontal lobes (b), and subcortical gray matter including thalamus, striatum and hippocampus (c). Other features such as periventricular white matter lesions are also captured as independent spatial components (d).

**Figure S4.** MRI medial temporal lobe phenotype of subjects stratified by the rs34173062 genotype class. The effects of age, sex, APOEε4 dosage and disease status have been partialled out.
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**Video S1**
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